Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

December 27, 2019 00:23:35
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?
Critical Care Perspectives in Emergency Medicine
Benzodiazepine-Refractory Status Epilepticus - Which Drug is Second-Line?

Dec 27 2019 | 00:23:35

/

Show Notes

Up to one-third of patients with status epilepticus will not respond to benzodiazepines.  Unfortunately, treatment of benzodiazepine-refractory status epilepticus is not well studied.  The longer seizures persist, the worse patients do.  In this podcast, we discuss the results of the recently completed ESETT trial that evaluated three anticonvulsant medications for status epilepticus.

You can get CME credit for this episode here!Click here for CME Account Creation Instructions

Other Episodes

Episode 0

January 06, 2020 00:34:59
Episode Cover

A Year in Review: Key Articles from the 2019 Critical Care Literature

A plethora of literature was published during the course of 2019.  In this podcast, we review several key articles published in the 2019 critical...

Listen

Episode 0

August 28, 2020 00:25:38
Episode Cover

Ketamine in the Critically Ill

Ketamine is a well-known anesthetic used commonly in the ED for RSI and procedural sedation.  In this podcast, we review the use of ketamine...

Listen

Episode 0

May 19, 2022 00:22:48
Episode Cover

Refractory OHCA - Does ECPR and Early Angiography Improve Outcome?

In a recent podcast we reviewed the ARREST Trial, which demonstrated significant improvement in survival among OHCA patients at a single center randomized to...

Listen